Riskpilot← Back to searchSign inGet full accessEpigard AB
ABActiveOrg 5566190434Forsvägen 7General medical practice activities · NACE 8621Est. 20020 employees
Revenue 2025
SEK 23K
EBITDA margin
-465.8%
+23% vs 2024
Equity ratio
79.3%
Financial strength
Net profit 2025
SEK 66K
-43% vs 2024
| Revenue | SEK 23K | — |
| EBITDA | SEK -108K | +23% |
| Net profit | SEK 66K | -43% |
| Total assets | SEK 711K | -28% |
| Equity | SEK 563K | -20% |
| Employees | 0 | — |
Legal name
Epigard AB
Org number
5566190434
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
25 januari 2002
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Föremålet för bolagets verksamhet är att bedriva sjukvård, informations- och utbildningsverksamhet inom sjukvården och därmed förenlig verksamhet.
Address
Forsvägen 7
Phone
+4687685153
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 432 | 167 | 23 | 0 | 23 |
| Staff expenses | — | −161 | −146 | −92 | −98 |
| EBITDA | 198 | −55 | −180 | −141 | −108 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 198 | −55 | −180 | −141 | −131 |
| Net financials | 7 | 4 | 15 | 19 | 55 |
| Profit before tax | 153 | 150 | 26 | 156 | 87 |
| Tax | −34 | −37 | −11 | −39 | −21 |
| Net profit | 119 | 113 | 15 | 117 | 66 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2 042 | 1 711 | 1 324 | 987 | 711 |
| Equity | 1 022 | 952 | 779 | 701 | 563 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 114 | 55 | 33 | 51 | 76 |
| Total debt | 114 | 55 | 33 | 51 | 76 |
EBITDA margin
-465.8%
This company
15.8%
Market median
-3048% vs market
20212025
Equity ratio
79.3%
This company
38.2%
Market median
+108% vs market
20212025
Return on equity
11.8%
This company
18.4%
Market median
+36% vs market
20212025
Net profit margin
285.3%
This company
8.1%
Market median
+3422% vs market
20212025
Asset turnover
0.03×
This company
1.12×
Market median
-97% vs market
20212025
Debt / equity
0.26×
This company
0.62×
Market median
+58% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-04-30
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
GE Audit | Audit | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2020 | |
| Deputy Board Member | 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Epigard AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Gun Elisabeth Holm | Audit | 0 companies |
| Kim Kjell-Åke Jarnald | Board of Directors | 0 companies |
| Marion Christina Jarnald | Deputy Board Member | 0 companies |